Last updated: March 1, 2026
What is NDC 70677-1189?
NDC 70677-1189 is a prescription drug listed in the National Drug Code directory. According to available data, this NDC corresponds to Aflibercept (Eylea), a monoclonal antibody used for treating conditions such as wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion.
Market Landscape
Therapeutic Area and Demand
Aflibercept (Eylea) dominates the anti-VEGF therapy market in ophthalmology. The global market for anti-VEGF agents is projected to grow significantly, driven by increasing prevalence of retinal diseases:
- Global prevalence: Estimated 196 million people affected by age-related macular degeneration (AMD) in 2020, expected to reach 288 million by 2040 (Flaxman et al., 2017).
- Market segmentation: Wet AMD accounts for about 10-15% of AMD cases but causes most vision loss.
Competitive Position
Eylea faces competition primarily from:
- Lucentis (ranibizumab)
- Beovu (brolucizumab)
These drugs are approved for similar indications and target the VEGF pathway.
Market Size and Revenue
In 2022, the global anti-VEGF market was valued at approximately $13 billion and is projected to grow at a compound annual growth rate (CAGR) of 8-10% through 2027 (Grand View Research, 2022). Key factors:
- Increasing patient population
- New indication approvals
- Extended dosing intervals improving compliance
Pricing and Reimbursement
Average wholesale prices (AWP) for Eylea are roughly $1,900 to $2,100 per dose in the U.S. (Medispan, 2023). Reimbursement varies based on payor policies, with common drug discounts, patient assistance programs, and evolving biosimilar policies influencing net prices.
Price Projections
Short-term (1-2 years)
- Price stability: Prices are expected to remain relatively stable, given minimal biosimilar competition as of 2023.
- Net price influence: Discounts and rebates may lead to net prices roughly 20-25% lower than list prices.
- Distribution: Significant sales are driven by hospital outpatient clinics and specialty pharmacies.
Mid-term (3-5 years)
- Biosimilar entry: Biosimilars for Eylea could enter the U.S. market by 2025-2026.
- Price decline projections: Biosimilar competition typically results in price reductions of 25-40%.
- Market share shifts: Biosimilar uptake expected to influence Eylea’s market share, potentially decreasing revenue by 15-30% depending on market penetration.
Long-term (5+ years)
- Pricing trends: Continued price erosion, possibly stabilizing around $1,300 to $1,700 per dose.
- Driver factors: Increased biosimilar adoption, potential novel therapies entering the market, and payer cost controls.
Regulatory and Policy Impact
The FDA approved a biosimilar for Eylea in 2022, with subsequent approval anticipated in major markets. This could accelerate price competition:
- U.S. biosimilar pathway: Facilitates entry, with pricing reductions of 20-30% within the first year of launch.
- Pricing regulation: CMS and private payors moving toward reimbursement models favoring biosimilars.
Additional Market Considerations
- Patent protection: Patent expiry for Eylea is projected around 2024-2027, opening pathways for biosimilar competition.
- R&D pipeline: Several pipeline therapies aim to improve upon current anti-VEGF options, potentially disrupting market share dynamics.
Summary Table of Price Projections
| Timeframe |
Expected Price Range (USD per dose) |
Factors |
| 2023-2024 |
$1,900 - $2,100 |
Stable, rebates influence net prices |
| 2025-2026 |
$1,400 - $1,700 |
Biosimilars launched, increased competition |
| 2027+ |
$1,300 - $1,600 |
Market normalization, new therapies |
Key Takeaways
- NDC 70677-1189 (Eylea) dominates its segment, with robust demand driven by a growing age-related retinal disease population.
- Market revenues for Eylea are expected to grow until biosimilars enter, after which significant price reductions are anticipated.
- Price stability now is likely to give way to deeper discounts post-biosimilar entry, with long-term prices stabilizing approximately 30-35% below current levels.
- Patent expiration and biosimilar approvals are primary catalysts for change in pricing and market shares in the coming 3-5 years.
- Policy and reimbursement shifts will impact net prices and access, especially in the U.S.
FAQs
Q1: When is biosimilar competition expected for Eylea?
A: Biosimilars are likely to enter the U.S. market around 2025-2026 after patent expiry.
Q2: What are the main indications for NDC 70677-1189?
A: Wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion-related macular edema.
Q3: How does biosimilar entry affect Eylea’s pricing?
A: Biosimilars typically cause a 25-40% price decrease, depending on market penetration and payor coverage.
Q4: What is the current average wholesale price for Eylea?
A: Approximately $1,900 to $2,100 per dose in the U.S.
Q5: How might new therapies impact Eylea’s market share?
A: Emerging treatments with improved efficacy or dosing could reduce Eylea’s market share and accelerate price declines.
References
[1] Flaxman, S. R., et al. (2017). Global causes of blindness and distance vision impairment 1990–2020: A systematic review and meta-analysis. Lancet Global Health, 5(12), e1221-e1234.
[2] Grand View Research. (2022). Anti-VEGF market size, trends, and forecasts.
[3] Medispan. (2023). Average wholesale prices and reimbursement data for ophthalmology drugs.
